Pozzilli P, et al. - Researchers explored the effect of dulaglutide on glycaemic control (HbA1c) in glutamic acid decarboxylase antibodies (GADA)-positive latent autoimmune diabetes of the adult (LADA) vs GADA-negative type-2 diabetes (T2D) patients using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D. Yielded results depicted that dulaglutide caused comparable HbA1c reductions in GADA-negative and GADA-positive patients at 12 months. Furthermore, HbA1c reductions were numerically, but not statistically, significantly larger in GADA-low patients vs GADA-high patients at 12 months. Hence, it was inferred that dulaglutide was effective in reducing HbA1c in LADA patients.